Xeris Biopharma Holdings, Inc. (XERS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '24: 187.4M Q4 '24: 203.1M Q1 '25: 222.6M Q2 '25: 246M Q3 '25: 266.1M Q4 '25: 291.8M Q1 '26: 314.9M Q2 '26: 335.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 100M 200M 300M Q3 '24: 151.2M Q4 '24: 165M Q1 '25: 181.7M Q2 '25: 201.1M Q3 '25: 223.7M Q4 '25: 248M Q1 '26: 269.1M Q2 '26: 289.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '24: -45.2M Q4 '24: -33.6M Q1 '25: -22.5M Q2 '25: -9.8M Q3 '25: 9.8M Q4 '25: 24.9M Q1 '26: 35.9M Q2 '26: 36.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q4 '23: -62.3M Q1 '24: -64.4M Q2 '24: -59.6M Q3 '24: -63.1M Q4 '24: -54.8M Q1 '25: -45.1M Q2 '25: -32M Q3 '25: -15.6M Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

Cost of Revenue TTM

0 20M 40M 60M Q3 '24: 34.9M Q4 '24: 36.8M Q1 '25: 39.6M Q2 '25: 43.7M Q3 '25: 41.1M Q4 '25: 42.6M Q1 '26: 44.4M Q2 '26: 45M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-40M -20M 0 20M 40M 60M Q3 '24: -31.5M Q4 '24: -37M Q1 '25: -26.7M Q2 '25: -16.2M Q3 '25: 10.6M Q4 '25: 28.6M Q1 '26: 48.5M Q2 '26: 56.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '24: 140.5M Q2 '24: 148.3M Q3 '24: 149M Q1 '25: 152.4M Q2 '25: 159.5M Q3 '25: 177.6M Q1 '26: 177.6M Q2 '26: 172.8M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.60 -0.40 -0.20 0.00 0.20 0.40 0.60 Q4 '23: -0.44 Q1 '24: -0.46 Q2 '24: -0.42 Q3 '24: -0.44 Q4 '24: -0.38 Q1 '25: -0.30 Q2 '25: -0.21 Q3 '25: -0.10 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.